secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bakhu Holdings, Corp. (—)
CIK:        0001440153
Form:       8-K
Filed at:   2026-06-30T19:07:58+00:00
Accession:  0001096906-26-001026
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 8.02, 8.01, 4.01, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bakhu Holdings signs funding deal with Phytocyte for 70% control; SEC inquiry over late filings
--------------------------------------------------------------------------------

- On April 7, 2026, Bakhu entered a Binding Heads of Agreement with Phytocyte for up to $250,000 funding, convertible to 70% of common stock upon compliance restoration.
- All prior officers and directors resigned between Jan 24-28, 2025; Efstathios Galazis served as sole director from June 2025 until March 18, 2026.
- Konstantia Galazi appointed sole director, President, CEO, Secretary and CFO on March 18, 2026; Karl E. Watkin appointed director on April 10, 2026.
- On March 24, 2026, the SEC inquired about Bakhu's failure to file mandatory periodic reports; company responded and requested time to file.
- The March 17, 2026 MOU with Phytocyte and Inter-M was terminated on April 17, 2026 due to insufficient funding after SEC inquiry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1440153/000109690626001026/0001096906-26-001026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1440153/000109690626001026/bkhu-20250124_8k.htm
  HTML page:      https://secwatch.observer/filing/0001096906-26-001026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer